DK1309575T3 - Biphenylderivater og deres anvendelse som aktivatorer af PPAR-gamma-receptorerne - Google Patents

Biphenylderivater og deres anvendelse som aktivatorer af PPAR-gamma-receptorerne

Info

Publication number
DK1309575T3
DK1309575T3 DK01965314T DK01965314T DK1309575T3 DK 1309575 T3 DK1309575 T3 DK 1309575T3 DK 01965314 T DK01965314 T DK 01965314T DK 01965314 T DK01965314 T DK 01965314T DK 1309575 T3 DK1309575 T3 DK 1309575T3
Authority
DK
Denmark
Prior art keywords
activators
ppar gamma
gamma receptors
biphenyl derivatives
biphenyl
Prior art date
Application number
DK01965314T
Other languages
English (en)
Inventor
Jean-Michel Bernardon
Laurence Clary
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Application granted granted Critical
Publication of DK1309575T3 publication Critical patent/DK1309575T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01965314T 2000-08-08 2001-08-03 Biphenylderivater og deres anvendelse som aktivatorer af PPAR-gamma-receptorerne DK1309575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0010447A FR2812876B1 (fr) 2000-08-08 2000-08-08 Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
PCT/FR2001/002543 WO2002012210A1 (fr) 2000-08-08 2001-08-03 Derives de biphenyle et leur utilisation comme activateurs des recepteurs ppar-gamma

Publications (1)

Publication Number Publication Date
DK1309575T3 true DK1309575T3 (da) 2005-09-12

Family

ID=8853412

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01965314T DK1309575T3 (da) 2000-08-08 2001-08-03 Biphenylderivater og deres anvendelse som aktivatorer af PPAR-gamma-receptorerne

Country Status (20)

Country Link
US (1) US6927228B2 (da)
EP (1) EP1309575B1 (da)
JP (1) JP2004505958A (da)
KR (1) KR20030051611A (da)
CN (1) CN1468226A (da)
AR (1) AR032888A1 (da)
AT (1) ATE297386T1 (da)
AU (2) AU8598101A (da)
BR (1) BR0113251A (da)
CA (1) CA2418895A1 (da)
DE (1) DE60111393T2 (da)
DK (1) DK1309575T3 (da)
ES (1) ES2245373T3 (da)
FR (1) FR2812876B1 (da)
MX (1) MXPA03001184A (da)
PL (1) PL360292A1 (da)
PT (1) PT1309575E (da)
RU (1) RU2280033C2 (da)
WO (1) WO2002012210A1 (da)
ZA (1) ZA200300667B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0013671A (pt) 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Derivados heterocìclicos para o tratamento do diabetes e outras doenças
WO2002072009A2 (en) * 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2002087576A1 (en) * 2001-04-30 2002-11-07 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
US7687664B2 (en) 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
JP2005500379A (ja) * 2001-08-17 2005-01-06 インサイト サンディエゴ インコーポレーテッド 異脂肪血症および高コレステロール血症を治療するオキシム誘導体
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
CA2468413A1 (en) 2001-12-14 2003-06-26 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
FR2836683B1 (fr) * 2002-03-01 2006-06-23 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
MXPA05003715A (es) 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
CA2503445C (en) * 2002-10-24 2012-07-31 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methylene urea derivatives as raf-kinase inhibitors
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
WO2004046091A2 (en) 2002-11-19 2004-06-03 Galderma Research & Development, S.N.C. Biaromatic compounds which activate ppar-gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
FR2847251B1 (fr) * 2002-11-19 2006-11-17 NOUVEAUX COMPOSES BI-AROMATIQUES ACTIVEURS DES RECEPTEURS DE TYPE PPARy ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
FR2847580B1 (fr) * 2002-11-25 2006-03-03 Galderma Res & Dev NOUVEAUX COMPOSES BI-AROMATIQUES ACTIVATEURS DES RECEPTEURS DE TYPE PPARy ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
PL376736A1 (pl) * 2002-11-25 2006-01-09 Galderma Research & Development, S.N.C. Nowe związki diaromatyczne, które aktywują receptor typu PPAR<$Egamma> i ich zastosowanie w kompozycjach kosmetycznych lub farmaceutycznych
CA2506732A1 (en) 2002-12-12 2004-06-24 Galderma Research & Development, S.N.C. Compounds which modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
FR2848553B1 (fr) * 2002-12-12 2007-03-30 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
ZA200509355B (en) * 2003-04-18 2007-03-28 Incyte San Diego Inc Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
JP4638423B2 (ja) * 2003-06-20 2011-02-23 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用
FR2856401B1 (fr) * 2003-06-20 2010-02-12 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
DE602005019555D1 (de) 2004-05-06 2010-04-08 Galderma Res & Dev Biaromatische verbindungen, die rezeptoren des typs ppar(gamma) aktivieren, verfahren zu deren herstellung und deren verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
FR2869903B1 (fr) 2004-05-06 2006-06-23 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppary, leur procede de preparation et leur utilisation dans les compositions cosmetiques ou pharmaceutiques
KR100619441B1 (ko) * 2004-06-30 2006-09-08 서울옵토디바이스주식회사 기판제거가 용이한 질화갈륨 성장 방법
FR2874379B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20070047308A (ko) 2004-08-17 2007-05-04 갈데르마 리써어치 앤드 디벨로프먼트 Ｐｐａｒ 유형 수용체를 활성화시키는 신규 이방향족화합물, 및 미용 또는 약학적 조성물에서의 그의 용도
FR2874378B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
RU2007109778A (ru) * 2004-08-17 2008-09-27 Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в косметических и фармацевтических композициях
JP2008520619A (ja) * 2004-11-19 2008-06-19 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγ受容体を調節する新規化合物並びに化粧品または製薬組成物中におけるその使用
FR2878247B1 (fr) 2004-11-19 2008-10-03 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US20080306054A1 (en) 2005-04-13 2008-12-11 Astex Therapeutics Limited Pharmaceutical Compounds
US20070059265A1 (en) * 2005-06-28 2007-03-15 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
US7943669B2 (en) * 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
FR2897536A1 (fr) * 2006-02-17 2007-08-24 Galderma Res & Dev Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20090099240A1 (en) * 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
FR2917084B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
FR2917086B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl acrylique activateurs des recepteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
JP2011502148A (ja) * 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2009129317A1 (en) * 2008-04-15 2009-10-22 Burnham Institute For Medical Research An inhibitor of anti-apoptotic proteins
PE20110551A1 (es) 2008-07-31 2011-09-02 Takeda Pharmaceutical Composicion farmaceutica solida que contiene un derivado de bencimidazol y un diuretico
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
PE20120593A1 (es) 2009-01-30 2012-05-21 Takeda Pharmaceutical Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
FR2969149B1 (fr) * 2010-12-16 2012-12-28 Oreal Procede de depigmentation des matieres keratiniques a l' aide de composes derives de resorcinol
SI2746265T1 (sl) 2011-08-18 2016-03-31 Nippon Shinyaku Co., Ltd. Heterociklični derivat kot zaviralec mikrosomske prostaglandin-e sintaze (mpges)
KR101485247B1 (ko) * 2012-06-26 2015-01-22 중앙대학교 산학협력단 신규 바이페닐―３―카르복스아마이드 유도체 또는 이의 염 및 이를 유효성분으로 함유하는 자가 면역질환 치료 또는 예방용 약학조성물
CN115925679A (zh) 2014-12-24 2023-04-07 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
CN118206542B (zh) * 2023-03-22 2025-06-27 沈阳药科大学 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
CN1468226A (zh) 2004-01-14
WO2002012210A1 (fr) 2002-02-14
ZA200300667B (en) 2004-02-11
ES2245373T3 (es) 2006-01-01
EP1309575A1 (fr) 2003-05-14
WO2002012210A9 (fr) 2002-04-18
US20040039038A1 (en) 2004-02-26
KR20030051611A (ko) 2003-06-25
RU2280033C2 (ru) 2006-07-20
US6927228B2 (en) 2005-08-09
AU2001285981B2 (en) 2006-01-19
AR032888A1 (es) 2003-12-03
BR0113251A (pt) 2003-06-24
AU8598101A (en) 2002-02-18
JP2004505958A (ja) 2004-02-26
FR2812876A1 (fr) 2002-02-15
EP1309575B1 (fr) 2005-06-08
FR2812876B1 (fr) 2002-09-27
DE60111393D1 (de) 2005-07-14
PT1309575E (pt) 2005-10-31
PL360292A1 (en) 2004-09-06
MXPA03001184A (es) 2003-10-15
CA2418895A1 (fr) 2002-02-14
ATE297386T1 (de) 2005-06-15
DE60111393T2 (de) 2006-03-23

Similar Documents

Publication Publication Date Title
DK1339679T3 (da) 3-Aroylindolderivater og deres anvendelse som agonister af CB2-receptorer
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1539712T3 (da) Pyrimidinderivater og deres anvendelse som CB2-modulatorer
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DE60111393D1 (de) Biphenylderivate und ihre verwendung als aktivatoren des ppar-gamma-rezeptors
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1246802T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
NO20043536L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
DK1394150T3 (da) 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
NO20034324L (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1272468T3 (da) Indolin-2-on-derivater og deres anvendelse som ligander for oxytocinreceptorerne
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
DK1578727T3 (da) Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
DK1309585T3 (da) Nye indolderivater og anvendelse af disse som lægemidler
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1537091T3 (da) Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
NO20030813D0 (no) Bifenylderivater og deres anvendelse som integrininhibitorer